Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex)

Recombinant interferon (IFN) β-1b was approved by the US Food and Drug Administration as the first disease-modifying therapy (DMT) for multiple sclerosis (MS) in 1993. Since that time, clinical trials and real-world observational studies have demonstrated the effectiveness of IFN therapies. The pivo...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohan, Stanley L., Hendin, Barry A., Reder, Anthony T., Smoot, Kyle, Avila, Robin, Mendoza, Jason P., Weinstock-Guttman, Bianca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258741/
https://www.ncbi.nlm.nih.gov/pubmed/34228301
http://dx.doi.org/10.1007/s40263-021-00822-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258741/
https://www.ncbi.nlm.nih.gov/pubmed/34228301
http://dx.doi.org/10.1007/s40263-021-00822-z

Ejemplares similares